NCT03785873已完成1 期
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 5
- 主要终点
- Median Progression-Free Survival (PFS)
研究概览
简要总结
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for patients with advanced or metastatic biliary tract cancer after progression on first-line systemic therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a pathologically confirmed carcinoma of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or gall bladder) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors with mixed hepatocellular and cholangiocarcinoma histology are excluded.
- •Patients must have received one and only one prior systemic therapy for advanced disease. Prior therapies must have not included irinotecan or PD- 1/PD-L1 antibody. Patient should have either progressed on or within 6 months of first-line systemic therapy or deemed intolerant of that therapy.
- •Prior surgical resection, radiation, chemoembolization, radioembolization or other local ablative therapies are permitted if completed ≥ 4 weeks prior to registration AND if patient has recovered to ≤ grade 1 toxicity.
- •Patients must have radiographically measurable disease (as per RECISTv1.1) in at least one site not previously treated with radiation or liver directed therapy (including bland, chemo- or radio-embolization, or ablation) either within the liver or in a metastatic lesion.
- •Age ≥18 years
- •Child-Pugh score of less than 7
- •ECOG performance status of 0-1
- •Ability to understand and willingness to sign IRB-approved informed consent
- •Available archived tissue (FFPE block or 20 unstained slides from prior core biopsy or surgery)
- •Must be able to tolerate CT and/or MRI with contrast
- •Adequate organ function (per protocol) assessed ≤2 weeks prior to registration
- •Must not have received systemic steroid therapy, or any other form of immunosuppressive therapy within 14 days prior to registration. Short bursts of steroids of 5-7 days (for COPD exacerbation or other similar indication) are allowed.
- •No prior history of solid organ transplantation or brain metastasis (unless treated, asymptomatic and stable).
- •Must not have undergone a major surgical procedure < 4 weeks prior to registration.
- •Must not have an active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ. Patients with history of malignancy are eligible provided primary treatment of that cancer was completed > 1 year prior to registration and the patient is free of clinical or radiologic evidence of recurrent or progressive malignancy.
- •Must have no ongoing active, uncontrolled infections (afebrile for > 48 hours off antibiotics).
- •Must not have received a live vaccine within 30 days of registration
- •Must not have a psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements.
- •Women must not be pregnant or breastfeeding since 5-fluorouracil, nal- irinotecan and/or nivolumab may harm the fetus or child. All females of childbearing potential (not surgically sterilized and between menarche and 1- year post menopause) must have a blood test to rule out pregnancy within 2 weeks prior to registration.
- •Women of child-bearing potential and men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation, and for 5 months (for women) and 7 months (for men) following completion of study therapy.
- •Participants with an active, known or suspected autoimmune disease which may affect vital organ function, or has/may require systemic immunosuppressive therapy for management are excluded. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of registration are excluded. Inhaled, ocular, intra-articular, intra-nasal or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- •No known UGT1A1* variants or Gilbert's syndrome
- •Prisoners or subjects who are involuntarily incarcerated, or compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness would be excluded.
- •No known hypersensitivity to 5-fluorouracil, leucovorin, irinotecan, and/or nivolumab.
- •Must not have ongoing bowel obstruction.
- •No known HIV, Hepatitis B or Hepatitis C infection that is untreated and/or with a detectable viral load.
- •Patients must not have uncontrolled intercurrent illness including, but not limited to, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia.
- •No known medical condition (e.g. a condition associated with uncontrolled diarrhea such as ulcerative colitis or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or interfere with the interpretation of safety results.
- •Patients must not be on warfarin, strong CYP3A4 inducers (such as phenytoin, phenobarbital, primidone, carbamazepine, rifampin, rifabutin, rifapentine or St. John's wort), strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole), and strong UGT1A1 inhibitors (such as atazanavir, gemfibrozil, indinavir and ketoconazole).
排除标准
- 未提供
研究组 & 干预措施
Nal-Irinotecan and Nivolumab
Experimental
干预措施: Nivolumab (Drug)
Nal-Irinotecan and Nivolumab
Experimental
干预措施: Nanoliposomal-Irinotecan (Drug)
Nal-Irinotecan and Nivolumab
Experimental
干预措施: 5-Fluorouracil (Drug)
Nal-Irinotecan and Nivolumab
Experimental
干预措施: Leucovorin (Drug)
结局指标
主要结局
Median Progression-Free Survival (PFS)
时间窗: Up to 2 years after last dose of study treatment, average of 4 months
Based on Kaplan-Meier estimates.
Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab
时间窗: At 4 weeks after initiation of study treatment
Adverse events will be graded according to NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.The patients accrued to the phase 2 portion of the trial were also observed for DLT during the first cycle of therapy given the same dose level was used.
次要结局
- Incidence of Treatment-related Adverse Events(Until discontinuation of study treatment, up to approximately 2 years after initiating study treatment or 3 years after first date of treatment initiation for those that remain on treatment)
- Overall Response Rate (ORR)(Up to 2 years after last dose of study treatment, average of 8.5 months)
- Median Overall Survival (OS)(Up to 2 years)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
A Study of Nivolumab in Selected Uterine Cancer PatientsUterine CancerEndometrial CarcinomaCarcinosarcomaUndifferentiated SarcomaHigh Grade Endometrial Stromal SarcomaLeiomyosarcomaClear Cell CarcinomaNCT03241745Memorial Sloan Kettering Cancer Center35
进行中（未招募）
2 期
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Thymoma Type B3Thymic CarcinomaNCT03134118European Organisation for Research and Treatment of Cancer - EORTC55
暂停
1 期
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaAggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 PositiveDiffuse Large B-Cell Lymphoma UnclassifiableIntravascular Large B-Cell LymphomaPrimary Mediastinal (Thymic) Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaNCT03704714Northwestern University30
招募中
2 期
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentCarcinoma, Squamous CellAnorectal CancerNCT06669572University of Chicago35
进行中（未招募）
1 期
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaOsteosarcomaOsteosarcoma in ChildrenOsteosarcoma RecurrentSarcomaNCT03628209H. Lee Moffitt Cancer Center and Research Institute21